【癌症治療 / IgG單克隆抗體】研究級生物仿製藥
癌症治療 IgG的單克隆抗體（mAb）| 研究級生物仿製藥
BioVision的研究級生物仿製藥。基於人IgG的單克隆抗體（mAb）是癌症治療中增長最快的類別。 幾種單克隆抗體已被FDA批准用於治療各種solid tumors實體瘤和hematological malignancies血液惡性腫瘤。 BioVision提供人IgG型式之的research grade biosimilars 研究級生物仿製藥以供應研究需求。 單克隆抗體使用具有來自治療性抗體的可變區的重組技術製造，以實現相似的安全性和功效。 這些抗體可用作臨床前鑑定之對照和用於開發新型治療劑之效力測定。主要特徵：無添加劑：在含有防腐劑的PBS緩衝液（0.02％Proclin 300）; 高純度：使用蛋白A> 98％純度; 多功能：可用於各種應用; ELISA，Neutralization，流式細胞術，IHC，IF
Immunofluorescent and Immunohistochemical staining using anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (Cat. No. A1096-200) (A & B) and Anti-CD52 (Campath-1H), Human IgG1 Antibody (Cat. No. A1105-200) (C & D).
抗CD20（利妥昔單抗）嵌合抗體 | 貨號A1049-100 Anti-CD20 (Rituximab), Chimeric Antibody
Rituximab產品介紹: Rituximab利妥昔單抗，一種靶向pan-B細胞標誌物CD20的嵌合單克隆抗體 已被證明被利妥昔單抗與CD20結合激活的細胞破壞機制，包括凋亡的直接信號轉導，補體激活和抗體依賴性細胞毒性。 Rituximab利妥昔單抗應用於治療各種B細胞惡性腫瘤。
| Cat # +Size | A1049-100 |
| Size | 100 µg |
| Antibody Target | CD20 |
| Alternate Name | MabThra |
| Host | Human/Mouse chimeric |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1 |
| Immunogen | CD20 |
| Accession # | NP_690605 |
| Gene ID | 54474 |
| Appearance | Colourless liquid |
| Formulation | In Phosphate buffered saline, pH 7.4. |
| Purification | Protein A chromatography. |
| Species Reactivity | Human |
| Application | Neutralization, ELISA |
| Application & Usage | Neutralization: 1-20 μg/ml; ELISA: 2μg/ml |
抗α5β1整合素（Volociximab）人IgG4抗體 | 貨號A1092-200 Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody
Volociximab產品介紹: Volociximab該抗體與a5ß1 integrin特異性結合，該蛋白是配體如fibronectin纖連蛋白，vitronectin玻連蛋白，laminins層粘連蛋白和collagens膠原之糖蛋白跨膜受體超家族的一部分。 a5ß1整合素受體在細胞過程如inflammation炎症，cell proliferation細胞增殖，angiogenesis血管生成和tumour metastasis腫瘤轉移中扮演關鍵作用。原始小鼠抗體的可變結構域，嵌合小鼠：該抗體的人IgG4版本已經在體內測試：在具有激光誘導的脈絡膜新血管形成（CNV）的cynomolgus monkeys食蟹猴中，在兔模型和人類志願者中。 該抗體用PDL Biopharma和Biogen-Idec達到II期臨床試驗。
更多抗體 抗CD20（利妥昔單抗） | 抗α5β1整合素（Volociximab） | Anti-HER2 (Trastuzumab) | 抗VEGF（Bevacizumab） | 抗EGFR（西妥昔單抗）嵌合抗體 | 抗CD11a（Efalizumab)） | Anti-PD-L1 (Atezolizumab)
| Cat # +Size | A1092-200 |
| Size | 200 µg |
| Antibody Target | ITGA5 |
| Alternate Name | Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e |
| Host | Recombinant |
| Antibody Type | Monoclonal |
| Isotype | Human IgG4, kappa |
| Immunogen | Heterodimeric α5β1Fc fusion protein |
| Accession # | P08648 |
| Gene ID | 3678 |
| Appearance | Colorless liquid |
| Formulation | 200 µg affinity purified human antibody in phosphate-buffered saline (PBS) containing 0.02% Proclin 300 |
| Purification | Affinity purified using protein A |
| Species Reactivity | Human |
| Application | ELISA; FC; IF; Block; IHC |
| Handling | The antibody solution should be gently mixed before use |
Anti-PD-L1 (Atezolizumab) 抗體 | 貨號A1089-100 Anti-PD-L1 (Atezolizumab), Humanized Antibody
Atezolizumab產品介紹: Atezolizumab（Tecentriq）是針對蛋白質程序性細胞死亡 – 配體1（PD-L1）的IgG1同種型的完全人源化，重組之單克隆抗體。 Atezolizumab阻斷PD-L1與PD-1的相互作用，並誘導抗腫瘤免疫再激活。
| Cat # +Size | A1305-100 |
| Size | 100 µg |
| Antibody Target | PD-L1 |
| Alternate Name | Tecentriq, PD-L1 |
| Host | Human |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1 |
| Immunogen | Human programmed cell death 1 ligand 1 (PD-L1) |
| Accession # | Q9NZQ7 |
| Gene ID | 29126 |
| Appearance | Colorless liquid |
| Formulation | In phosphate buffered saline, pH 7.4 |
| Purification | Affinity purified |
| Species Reactivity | Human |
| Application | Neutralization, ELISA |
| Application & Usage | Neutralization: 0.1-1 μg/ml, ELISA: 1 μg/ml |
抗CD11a（Efalizumab)）人IgG1抗體 | 貨號A1089-100 Anti-CD11a (Efalizumab), Human IgG1 Antibody
Efalizumab產品介紹: 整合素α-L /β-2是ICAM1，ICAM2，ICAM3和ICAM4的受體。 它涉及各種免疫現象，包括白細胞 – 內皮細胞相互作用，細胞毒性T細胞介導的殺傷和粒細胞和單核細胞的抗體依賴性殺傷。
| Cat # +Size | A1089-200 |
| Size | 200 µg |
| Antibody Target | ITGAL |
| Alternate Name | LFA-1; integrin alpha L |
| Host | Recombinant |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1, kappa |
| Immunogen | Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. |
| Accession # | P20701 |
| Gene ID | 3683 |
| Appearance | Colorless liquid |
| Formulation | 200 µg affinity purified human antibody in phosphate-buffered saline (PBS) containing 0.02% Proclin 300 |
| Purification | Affinity purified using protein A |
| Species Reactivity | Human |
抗EGFR（西妥昔單抗）嵌合抗體 | 貨號A1047-100 Anti-EGFR (Cetuximab), Chimeric Antibody
Cetuximab產品介紹: Anti-EGFR (Cetuximab)西妥昔單抗是重組人/小鼠嵌合表皮生長因子受體（EGFR）單克隆抗體。 表皮生長因子受體（EGFR）是在正常細胞和腫瘤細胞上發現的對細胞生長重要的受體。 Cetuximab西妥昔單抗是一種EGFR抑制劑，用於通過阻斷EGFR的活性並防止癌症生長而治療癌症。 Cetuximab西妥昔單抗可以通過與腫瘤細胞上的EGFR結合而形成觸發免疫反應的橋樑。 它用於治療表達EGFR的轉移性結腸直腸癌。
| Cat # +Size | A1047-100 |
| Size | 100 µg |
| Antibody Target | EGFR |
| Alternate Name | Erbitux |
| Host | Human/Mouse chimeric |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1 |
| Immunogen | Human A431 cells |
| Accession # | AAI18666 |
| Gene ID | 1956 |
| Appearance | Colourless liquid |
| Formulation | In Phosphate buffered saline, pH 7.4. |
| Purification | IgG purified from murine cell culture supernatant by protein A chromatography |
| Species Reactivity | Human |
| Application | Neutralization, ELISA |
| Application & Usage | Neutralization : 1-20 μg/ml; ELISA: 2μg/ml |
抗VEGF（Bevacizumab）人源化抗體 | 貨號A1045-100 Anti-VEGF (Bevacizumab), humanized Antibody
Bevacizumab（Avastin）產品介紹: Bevacizumab貝伐單抗（Avastin）是重組人源化單克隆IgG1抗體。 貝伐珠單抗，靶向血管內皮生長因子（VEGF）的細胞表面蛋白導致抑制腫瘤生長。 VEGF在發育性血管生成中扮演重要作用，對reproductive生殖和bone angiogenesis骨血管生成也很重要。Avastin用於治療各種癌症如metastatic colorectal cancer轉移性結腸直腸癌，non-squamous non–small cell lung cancer非鱗狀非小細胞肺癌，metastatic breast cancer轉移性乳腺癌，glioblastoma膠質母細胞瘤和metastatic renal cell carcinoma.轉移性腎細胞癌。
| Cat # +Size | A1045-100 |
| Size | 100 µg |
| Antibody Target | VEGF |
| Alternate Name | Avastin |
| Host | Human |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1 |
| Immunogen | Recombinant human VEGF |
| Accession # | AAP86646 |
| Gene ID | 7422 |
| Appearance | Colourless liquid |
| Concentration | 2 mg/ml |
| Formulation | 100 ug (2mg/ml) of antibody in Phosphate buffered saline, pH 7.4. |
| Purification | human IgG1 was expressed in a human cell line. IgG was purified from CHO cell culture supernatant by protein A chromatography. |
| Species Reactivity | Human |
| Application | Neutralization, ELISA |
| Application & Usage | Neutralization: 0.1-20 μg/ml, ELISA: 2 μg/ml |
Anti-HER2 (Trastuzumab), humanized Antibody | 貨號A1046-100 Monoclonal human IgG1 antibody against human HER2
Trastuzumab曲妥單抗產品介紹: Trastuzumab曲妥單抗是recombinant humanized重組人源化單克隆免疫球蛋白G1 kappa antibody，其以高親和力和extracellular domain of the HER2 receptor HER2受體的細胞外結構域具特異性結合。 生殖因子receptor gene受體基因，人表皮生長因子受體（HER2）在25％至30％的乳腺癌中被擴增; 編碼的蛋白質在惡性細胞中以非常高的水平存在。 Trastuzumab曲妥珠單抗用於治療佐劑和轉移性乳腺癌以及轉移性胃癌。
| Cat # +Size | A1046-100 |
| Size | 100 µg |
| Antibody Target | HER2 |
| Alternate Name | Herceptin |
| Host | Human |
| Antibody Type | Monoclonal |
| Isotype | Human IgG1 |
| Immunogen | Recombinant human epidermal growth factor receptor 2 (HER2) |
| Accession # | P04626 |
| Gene ID | 2064 |
| Appearance | Colourless liquid |
| Formulation | 100 ug of antibody in Phosphate buffered saline, pH 7.4. |
| Purification | IgG purified from CHO culture supernatant by protein A chromatography |
| Species Reactivity | Human |
| Application | Neutralization, ELISA |
| Application & Usage | Neutralization : 1-20 μg/ml; ELISA: 2μg/ml |
| Handling | The antibody solution should be gently mixed before use. |
| Cat. No. | Product Name | Trade Name | Isotype | Size |
| A1045-100 | Anti-VEGF (Bevacizumab), humanized Antibody | Avastin | Human IgG1 | 100 µg |
| A1046-100 | Anti-HER2 (Trastuzumab), humanized Antibody | Herceptin | Human IgG1 | 100 µg |
| A1047-100 | Anti-EGFR (Cetuximab), Chimeric Antibody | Erbitux | Human IgG1 | 100 µg |
| A1048-100 | Anti-TNF-α (Adalimumab), humanized Antibody | Humira | Human IgG1 | 100 µg |
| A1049-100 | Anti-CD20 (Rituximab), Chimeric Antibody | Mabthera | Human IgG1 | 100 µg |
| A1050-100 | Anti-EGFR (Panitumumab), humanized Antibody | Vectibix | Human IgG1 | 100 µg |
| A1088-200 | Anti-OX40L (Oxelumab), Human IgG1 Antibody | Xolair | Human IgG1 | 200 µg |
| A1089-200 | Anti-CD11a (Efalizumab), Human IgG1 Antibody | Raptiva | Human IgG1 | 200 µg |
| A1090-200 | Anti-EGFR (Matuzumab), Human IgG1 Antibody | Matuzumab | Human IgG1 | 200 µg |
| A1091-200 | Anti-CD4 (Clenoliximab), Human IgG4 Antibody | Clenoliximab | Human IgG4 | 200 µg |
| A1092-200 | Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody | Volociximab | Human IgG4 | 200 µg |
| A1093-200 | Anti-TNF alpha (Humicade), Human IgG4 Antibody | Humicade | Human IgG4 | 200 µg |
| A1094-200 | Anti-CD40L (Ruplizumab), Human IgG1 Antibody | Antova | Human IgG1 | 200 µg |
| A1096-200 | Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody | CEA-Scan | Human IgG1 | 200 µg |
| A1097-200 | Anti-TNF alpha (Infliximab), Human IgG1 Antibody | Remicade | Human IgG1 | 200 µg |
| A1098-200 | Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody | Simulect | Human IgG1 | 200 µg |
| A1099-200 | Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody | Zenapax | Human IgG1 | 200 µg |
| A1105-200 | Anti-CD52 (Campath-1H), Human IgG1 Antibody | Campath | Human IgG1 | 200 µg |
| A1305-100 | Anti-PD-L1 (Atezolizumab), Humanized Antibody | Tecentriq | Human IgG1 | 100 µg |
| A1306-100 | Anti-PD-1 (Pembrolizumab), Humanized Antibody | Keytruda | Human IgG1 | 100 µg |
| A1307-100 | Anti-PD-1 (Nivolumab), Humanized Antibody | Opdivo | Human IgG1 | 100 µg |